公海彩船: 课题组长
姓名:
程建军助理教授 研究员 博士生导师, PhD, 助理教授
职务:
所在院所:
荣誉称号:
教育经历:
-
2001/09—2005/06,山东大学,学士
-
2005/09—2010/07,中国科公海彩船上海药物研究所,博士
博士后及工作经历:
- 2010/07—2013/10,上海汇伦生命科技,高级研究员
- 2013/11—2016/03,伊利诺伊大学芝加哥分校,博士后
- 2016/03—2022/06,上海科技大学,iHuman研究所,副研究员、课题组长
- 2022/07—至今,上海科技大学,公海彩船/iHuman研究所,助理教授(TENURE-TRACK)
公海彩船: 课题组简介
研究内容:
1. 基于单胺类GPCR的抗精神疾病药物发现
精神类疾病如精神分裂症、抑郁症主要是与多巴胺受体、血清素受体等单胺类GPCR的功能异常相关。我们以单胺类GPCR为靶标,以“受体-配体”复合物结构为指导,设计合成具有受体亚型高选择性或信号通路“偏向性”的新型小分子化合物,并进行相应的药理药效研究,以获得具有更优药效、更少毒副作用的新型抗精神疾病候选药物。 2. 基于腺苷信号通路的抗肿瘤药物发现 肿瘤微环境中,腺苷是重要的免疫抑制因子。腺苷通过激活腺苷受体发挥免疫抑制作用,而腺苷受体拮抗剂能够拮抗腺苷的免疫抑制作用发挥抗肿瘤活性。我们以腺苷受体为靶标,进行具有新机制的小分子药物的设计合成,并研究其抗肿瘤活性,以获得新型抗肿瘤候选药物。
公海彩船: 研究成果展示
基于致幻剂机制的新型5-HT2A受体激动剂设计与抗抑郁活性研究(Science 2022;Chem Rev 公海彩船) 基于多巴胺D2受体部分激动剂的新型抗精神分裂症药物发现(Nat Neurosci 2022;J Med Chem 2021, 公海彩船) 具有抗精神分裂症活性的新型GPR139激动剂发现(J Med Chem 公海彩船) 基于PCPMA优势骨架的药物设计(J Med Chem 2020,2021) 腺苷A2a受体拮抗/HDAC活性抑制的双功能抗肿瘤化合物(J Med Chem 2021,公海彩船; Eur J Med Chem 2022)
公海彩船: 代表性论文(*第一作者,#通讯作者)
- 1. Duan, Wenwen*; Cao, Dongmei; Wang, Sheng#; Cheng, Jianjun#; .Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.CHEMICAL REVIEWS. 公海彩船. 124(1):124-163.
- 2. Liu, Ruiquan*; Duan, Wenwen; Yan, Wenzhong; Zhang, Jinfeng; Cheng, Jianjun#; .Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A 2A adenosine receptors and histone deacetylases.CHINESE CHEMICAL LETTERS. 公海彩船. 35(1).
- 3. Li, Huiqiong*; Cheng, Jianjun#.2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design.BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS. 公海彩船. 101: 129654.
- 4. Jianhang Mao*; Yilong Cui; Huan Wang; Wenwen Duan; Zhi-Jie Liu; Tian Hua*; Ning Zhou#; Jianjun Cheng#; .Design and Synthesis of Novel GPR139 Agonists with Therapeutic Effects in Mouse Models of Social Interaction and Cognitive Impairment.JOURNAL OF MEDICINAL CHEMISTRY. 13 Oct 公海彩船. 66(20):14011–14028.
- 5. Liu, Ruiquan*; Qi, Jianzhong; Wang, Huan; Fan, Luyu; Zhang, Pei; Yu, Jing; Tan, Liang; Wang, Sheng#; Cheng, Jianjun#; .Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents.JOURNAL OF MEDICINAL CHEMISTRY. 11 May 公海彩船. 66(9).
- 6. Sun, Nan*; Yang, Kexin; Yan, Wenzhong; Yao, Mingyue; Xie, Chengying#; Cheng, Jianjun#; Yu, Chengcheng; Duan, Wenwen; Gu, Xiaoke; Guo, Dong; Jiang, Hualiang; .Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response.JOURNAL OF MEDICINAL CHEMISTRY. 01 Mar 公海彩船.
- 7. Zhang, Jinfeng*; Feng, Dandan; Cheng, Jianjun#; Wüthrich, Kurt#; .Adenosine A2AReceptor (A2AAR) Ligand Screening Using the 19F-NMR Probe FPPA.JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 公海彩船. 145(28):15061-15064.
- 8. Cao, Dongmei*; Yu, Jing; Wang, Huan; Luo, Zhipu; Liu, Xinyu; He, Licong; Qi, Jianzhong; Fan, Luyu; Tang, Lingjie; Chen, Zhangcheng; Li, Jinsong; Cheng, Jianjun#; Wang, Sheng#; .Structure-based discovery of nonhallucinogenic psychedelic analogs.SCIENCE. 28 Jan 2022. 375(6579).
- 9. Chen, Zhangcheng*; Fan, Luyu; Wang, Huan; Yu, Jing; Lu, Dengyu; Qi, Jianzhong; Nie, Fen; Luo, Zhipu; Liu, Zhen; Cheng, Jianjun#; Wang, Sheng#; .Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties.NATURE NEUROSCIENCE. Jan 2022.
- 10. Wang, Jingjing*; Wu, Meng; Chen, Zhangcheng; Wu, Lijie; Wang, Tian; Cao, Dongmei; Wang, Huan; Liu, Shenhui; Xu, Yueming; Li, Fei; Liu, Junlin; Chen, Na; Zhao, Suwen; Cheng, Jianjun#; Wang, Sheng#; Hua, Tian#; .The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands.NATURE COMMUNICATIONS. 23 May 2022. 13(1).
- 11. Gu, Xiaoke*; Yuan, Haoxing; Zhao, Wenchao; Sun, Nan; Yan, Wenzhong; Jiang, Chunyu; He, Yan; Liu, Hongli; Cheng, Jianjun#; Guo, Dong#; .Optical-Controlled Kinetic Switch: Fine-Tuning of the Residence Time of an Antagonist Binding to the Vasopressin V2 Receptor in In Vitro, Ex Vivo, and In Vivo Models of ADPKD.JOURNAL OF MEDICINAL CHEMISTRY. 01 Dec 2022. 66(2).
- 12. Zhang, Jinfeng*; Luo, Ziwei; Duan, Wenwen; Yang, Kexin; Ling, Lijun; Yan, Wenzhong; Liu, Ruiquan; Wuthrich, Kurt; Jiang, Hualiang#; Xie, Chengying#; Cheng, Jianjun#; .Dual-acting antitumor agents targeting the A 2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H- pyrazolo[3,4-d]pyrimidin-6-amine derivatives.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 05 Jun 2022. 5(236):1-14.
- 13. Zhang, Haoran*; Yan, Wenzhong; Sun, Yongzhan; Yuan, Haoxing; Su, Limin; Cao, Xudong; Wang, Peng; Xu, Zhou; Hu, Youhui; Wang, Zhongjian; Wang, Yinan; Fu, Kequan; Sun, Ying; Chen, Yupeng#; Cheng, Jianjun#; Guo, Dong#; .Long Residence Time at the Vasopressin V-2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease.JOURNAL OF MEDICINAL CHEMISTRY. 09 Jun 2022. 65(11).
- 14. Yan, Wenzhong*; Ling, Lijun; Wu, Yiran; Yang, Kexin; Liu, Ruiquan; Zhang, Jinfeng; Zhao, Simeng; Zhong, Guisheng; Zhao, Suwen; Jiang, Hualiang#; Xie, Chengying#; Cheng, Jianjun#; .Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A(2A) Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents.JOURNAL OF MEDICINAL CHEMISTRY. 25 Nov 2021. 64(22).
- 15. Yan, Wenzhong*; Fan, Luyu; Yu, Jing; Liu, Ruiquan; Wang, Huan; Tan, Liang; Wang, Sheng#; Cheng, Jianjun#; .2-Phenylcyclopropylmethylamine Derivatives as Dopamine D-2 Receptor Partial Agonists: Design, Synthesis, and Biological Evaluation.JOURNAL OF MEDICINAL CHEMISTRY. 09 Dec 2021. 64(23).
- 16. Duan, Wenwen*; Sun, Ying; Wu, Meng; Zhang, Zhiyuan; Zhang, Taotao; Wang, Huan; Li, Fei; Yang, Lingyun; Xu, Yueming; Liu, Zhi-Jie; Hua, Tian#; Nie, Hong#; Cheng, Jianjun#; .Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 15 Dec 2021. 226.
- 17. Chan, H. C. Stephen*; Xu, Yueming; Tan, Liang; Vogel, Horst; Cheng, Jianjun#; Wu, Dong#; Yuan, Shuguang#; .Enhancing the Signaling of GPCRs via Orthosteric Ions.ACS CENTRAL SCIENCE. 26 Feb 2020. 6(2):274-282.
- 18. Fan, Luyu*; Tan, Liang; Chen, Zhangcheng; Qi, Jianzhong; Nie, Fen; Luo, Zhipu; Cheng, Jianjun#; Wang, Sheng#; .Haloperidol bound D-2 dopamine receptor structure inspired the discovery of subtype selective ligands.NATURE COMMUNICATIONS. 26 Feb 2020. 11(1).
- 19. Zhang, Jinfeng*; Yan, Wenzhong; Duan, Wenwen; Wuthrich, Kurt; Cheng, Jianjun#; .Tumor Immunotherapy Using A(2A) Adenosine Receptor Antagonists.PHARMACEUTICALS. Sep 2020. 13(9).
- 20. Tan, Liang*; Zhou, Qingtong; Yan, Wenzhong; Sun, Jian; Kozikowski, Alan P.; Zhao, Suwen; Huang, Xi-Ping#; Cheng, Jianjun#; .Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands.JOURNAL OF MEDICINAL CHEMISTRY. 14 May 2020. 63(9):4579-4602.
- 21. Tan, Liang*; Yan, Wenzhong; McCorvy, John D.#; Cheng, Jianjun#; .Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.JOURNAL OF MEDICINAL CHEMISTRY. 22 Nov 2018. 61(22):9841-9878.
公海彩船: 奖励
- 1. 公海彩船,上海科技大学优秀教师
- 2. 2022,上海市优秀学术带头人
- 3. 2020,上海科技大学优秀员工
- 4. 2017,上海高校青年东方学者
公海彩船: 加入我们
课题组招聘1-2名具有药物化学或相关背景的博士后,从事基于GPCR结构和功能的药物设计研究。有意者请邮件联系。
公海彩船: 课题组成员及合影
-
姓名:王欢
身份:副研究员
在组时间:2018-至今
邮箱:wanghuan1@shanghaitech.edu.cn
-
姓名:闫文仲
身份:助理研究员
在组时间:2017-至今
邮箱:yanwzh@shanghaitech.edu.cn
-
姓名:张金凤
身份:博士后
在组时间:2022-至今
邮箱:zhangjf4@shanghaitech.edu.cn
-
姓名:黎慧琼
身份:博士研究生
在组时间:2022-至今
邮箱:lihq@shanghaitech.edu.cn
-
姓名:李荣研
身份:硕士研究生
在组时间:2021-至今
邮箱:liry@shanghaitech.edu.cn
-
姓名:刘洋洋
身份:硕士研究生
在组时间:2021-至今
邮箱:liuyy3@shanghaitech.edu.cn
-
姓名:陈玉晋
身份:硕士研究生
在组时间:2022-至今
邮箱:chenyj2022@shanghaitech.edu.cn
-
姓名:黄瑞
身份:硕士研究生
在组时间:2022-至今
邮箱:huangrui2022@shanghaitech.edu.cn
-
姓名:吉忻
身份:硕士研究生
在组时间:2022-至今
邮箱:jixin2022@shanghaitech.edu.cn
-
姓名:李会林
身份:硕士研究生
在组时间:2022-至今
邮箱:lihl2022@shanghaitech.edu.cn
-
姓名:孙睿康
身份:硕士研究生
在组时间:公海彩船-至今
邮箱:srk@shanghaitech.edu.cn
-
姓名:王梦园
身份:硕士研究生
在组时间:公海彩船-至今
邮箱:wangmy公海彩船@shanghaitech.edu.cn
-
姓名:李天恒
身份:本科生
在组时间:公海彩船/06-至今
邮箱:lith2022@shanghaitech.edu.cn
-
姓名:毛建航
身份:硕士研究生
在组时间:2020-公海彩船
邮箱:maojh@shanghaitech.edu.cn
|